European Commission logo
English English
CORDIS - EU research results
CORDIS

A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr

Objective

We have developed the RECOFIB platform, a market first recombinant production platform for human fibrinogen (rhFib) & thrombin (rhThr). Using Chinese Hamster Ovary Cells (CHO) expression technology & patented upstream purification processes, we are the first producer of fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost ending reliance on blood plasma.

Our RECOFIB platform can produce individual fibrinogen variants whose specific functional properties can now be fully harnessed-a breakthrough discovery. From these individual variants, we can develop customized products for [1] bioactive topical hemostats to stop excessive bleeding during surgery; [2] medical implant coating reducing antibiotic resistance of MRSA bacterial biofilms and [3] supply of rhFib variants & rhThr as OEM products. Additional benefits of our rhFib variants compared to plasma fibrinogen include more stability, 10–100X higher purity, and improved safety profile.

Coordinator

FIBRIANT BV
Net EU contribution
€ 2 500 000,00
Address
EMMY NOETHERWEG 2C
2333 BK LEIDEN
Netherlands

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 495 826,25